Skip to content
Open access

Regulatory Challenges of Medicinal Cannabis in Australia and the United Kingdom: Insights from a Research Landscape Analysis

2026 · International journal of research and innovation in social science · 0 citations

Abstract

The legalisation of medicinal cannabis has increasingly shifted the regulatory debate from whether cannabis should be permitted for medical purposes to how effective governance can ensure safe, equitable and meaningful patient access. Although Australia and the United Kingdom have established legal pathways for medicinal cannabis, legal recognition does not necessarily translate into practical accessibility. Patients may continue to encounter restrictive prescribing requirements, limited professional knowledge and confidence, uncertainty surrounding clinical evidence, product availability and quality, affordability concerns, and regulatory complexity. This study aims to examine the legal and governance frameworks governing medicinal cannabis in Australia and the United Kingdom and to identify the principal regulatory and practical challenges affecting their implementation. A qualitative research landscape analysis was undertaken using Scopus AI Analytics to examine relevant literature on medicinal cannabis regulation, legislation, governance and implementation challenges in the two jurisdictions. The analysis incorporated the Summary, Expanded Summary and Concept Map functions to identify key regulatory relationships and developing areas of research. The findings indicate that the central governance challenge in both jurisdictions is the need to balance regulatory control with meaningful patient access. Australia demonstrates a complex, multi-level regulatory structure involving federal and state or territory authorities, while the United Kingdom operates a more restrictive specialist prescribing framework. Across both jurisdictions, regulatory effectiveness is influenced not only by legislation but also by professional preparedness, clinical evidence, product safety and quality, market availability, affordability and mechanisms for monitoring patient outcomes. The study suggests that medicinal cannabis governance should be understood as an interconnected and adaptive regulatory system rather than a purely legislative exercise. Practically, policymakers should strengthen regulatory coordination, professional education, evidence-based prescribing, product oversight and patient protection while ensuring that regulatory requirements do not unnecessarily impede access. The findings provide a basis for developing more proportionate, responsive and patient-centred approaches to medicinal cannabis governance.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.